Veego Pharma LLC, promoter of Wintac, has announced the floor price for its proposed delisting offer at ₹220 a share. The delisting proposal of the promoter is subject to approval by the board of directors, shareholders (through postal ballot) and other statutory and regulatory authorities.
Wintac, which focuses on the manufacture of small and large volume parenterals, sterile ophthalmic preparations and also marketing of pharmaceutical specialities catering to niche segments, had reported a loss of ₹0.59 crore for the quarter-ended December 2017 on revenues of ₹10.41 crore.
On Thursday, the shares of Wintac closed at ₹195.40, a gain of 5 per cent on the BSE. Our Bureau